There is no specific BMI threshold to qualify for Ozempic because Ozempic is not FDA-approved for weight loss. It’s approved for managing type 2 diabetes. If you have type 2 diabetes, your doctor can prescribe Ozempic regardless of your BMI. The medication most people are actually looking for is Wegovy, which contains the same active ingredient (semaglutide) but is specifically approved for weight management with clear BMI cutoffs.
Ozempic vs. Wegovy: Same Drug, Different Rules
Ozempic and Wegovy both contain semaglutide, but the FDA approved them for different purposes. Ozempic is approved for managing type 2 diabetes, improving kidney and cardiovascular health in adults with type 2 diabetes and chronic kidney disease, and reducing cardiovascular risk in adults with type 2 diabetes and heart disease. There is no minimum BMI required for any of these uses. You need a type 2 diabetes diagnosis.
Wegovy is the version approved for weight management in adults and children 12 and older. It’s also approved for treating a form of fatty liver disease and for reducing cardiovascular risk in adults with obesity or overweight who have heart disease. When doctors prescribe semaglutide specifically for weight loss, Wegovy is the on-label option, and that’s where BMI thresholds come into play.
Some doctors do prescribe Ozempic off-label for weight loss, meaning they use it for a purpose the FDA hasn’t officially approved. In those cases, the doctor sets their own criteria, but insurance companies rarely cover off-label use for weight management.
The BMI Thresholds for Wegovy
The FDA-approved criteria for Wegovy follow two paths:
- BMI of 30 or higher: You qualify based on BMI alone. This is the clinical definition of obesity.
- BMI of 27 to 29.9: You qualify if you also have at least one weight-related health condition.
These same thresholds (30 or 27-plus-comorbidity) are echoed in the 2025 VA/DoD clinical practice guidelines for obesity pharmacotherapy and are the standard most prescribers follow. For adolescents aged 12 and older, the qualification is based on having a BMI at or above the 95th percentile for their age and sex, which is the pediatric definition of obesity.
Qualifying Health Conditions at BMI 27
If your BMI falls between 27 and 29.9, you’ll need a documented weight-related comorbidity. The conditions that typically count include high blood pressure, type 2 diabetes, high cholesterol or triglycerides, obstructive sleep apnea, osteoarthritis, nonalcoholic fatty liver disease, and metabolic syndrome.
Metabolic syndrome alone covers a wide range of people. It’s defined as meeting three of five criteria: a large waist circumference (over 40 inches for men, over 35 inches for women), elevated triglycerides, low HDL cholesterol, blood pressure above 130/85, or prediabetes. Many people with a BMI in the 27 to 30 range already meet this definition without realizing it.
What Insurance Actually Requires
Meeting the FDA criteria doesn’t guarantee your insurance will pay for the medication. A study from the Tufts Center for the Evaluation of Value and Risk in Health found that while many commercial health plans do follow the labeled BMI thresholds (30, or 27 with a comorbidity), they often layer on additional requirements through prior authorization.
Common extra hurdles include documentation that you’ve already tried diet and exercise programs, sometimes for a specific number of months. Some plans require evidence that you’ve attempted other weight loss medications first. Others exclude weight management drugs from coverage entirely. The prior authorization process typically requires your doctor to submit medical records showing your BMI, relevant diagnoses, and previous weight loss attempts.
Some health systems set their own stricter cutoffs. Certain facilities, for example, reserve semaglutide for patients with a BMI of 40 or higher, or 35 and above with difficult-to-manage comorbidities. These are institutional decisions driven by cost and supply, not FDA rules.
When BMI Doesn’t Tell the Whole Story
BMI is a blunt tool. It doesn’t distinguish between muscle and fat, and it misses people who carry dangerous visceral fat around their organs but fall below the 30 threshold on the scale. Some prescribing guidelines now acknowledge this. The 2025 VA/DoD guidelines note that patients with a BMI between 25 and 27 who show additional measures of excess body fat “require special considerations,” signaling that BMI alone may not capture everyone who could benefit.
Mississippi’s medical licensing board, as one example, lists alternative qualifying measures beyond BMI: body fat above 30% in women or 25% in men, a waist-to-hip ratio indicating elevated cardiovascular risk, or a current body weight at least 120% of a well-documented healthy weight maintained after age 18. These alternative pathways aren’t universally accepted, but they reflect a growing recognition that the number on a BMI chart isn’t the final word.
How to Find Out If You Qualify
Your fastest path is to calculate your BMI (weight in pounds divided by height in inches squared, multiplied by 703) and check whether you fall above 30 or above 27 with a relevant health condition. If you’re looking for semaglutide specifically for weight loss, ask your doctor about Wegovy rather than Ozempic. Prescribing Wegovy on-label gives you the best chance of insurance coverage and avoids the complications of off-label prescribing.
If your BMI is close to the cutoff, bring any existing diagnoses of high blood pressure, sleep apnea, prediabetes, or joint problems to your appointment. These conditions are often already in your medical record and can make the difference between qualifying and being turned away. If your insurance denies coverage, your doctor can sometimes file an appeal with additional clinical documentation, though approval is never guaranteed.